Related references
Note: Only part of the references are listed.Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
Alessandra Iurlo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities
Olga K. Weinberg et al.
HAEMATOLOGICA (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
Ayalew Tefferi et al.
LEUKEMIA (2018)
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
Ayalew Tefferi et al.
LEUKEMIA (2018)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi et al.
LEUKEMIA (2018)
Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis
Mythri Mudireddy et al.
BLOOD CANCER JOURNAL (2018)
Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities
Olga K. Weinberg et al.
HAEMATOLOGICA (2018)
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Lucia Masarova et al.
BLOOD (2018)
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes
Caroline J. McNamara et al.
BLOOD ADVANCES (2018)
Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients
Umberto Gianelli et al.
HISTOPATHOLOGY (2017)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2017)
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
Paola Guglielmelli et al.
BLOOD (2017)
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
Malte Asshoff et al.
BLOOD (2017)
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients
Paola Guglielmelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
Shinsuke Takagi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Secondary Acute Myeloid Leukemias Arising From Philadelphia Chromosome Negative Myeloproliferative Neoplasms: Pathogenesis, Risk Factors, and Therapeutic Strategies
Michael Tallarico et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms
Mario Cazzola et al.
BLOOD (2014)
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
Raajit Rampal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation
Stefan O. Ciurea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Share Paper
